3 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.
Approved WMOWill not start
To evaluate Multiple Independent Current Control (MICC) perception and sub-perception based programming at Dorsal Column (DC) targets and Dorsal Root (DR) targets for focal foot, knee, or groin pain relief.